一名多发性硬化症患者使用阿仑单抗后出现全秃和短暂性调节痉挛。
Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis.
作者信息
Tzanetakos Dimitrios, Breza Marianthi, Tzartos John S, Bontzos Georgios, Vakrakou Aigli G, Dermentzoglou Alexandros, Gkizis Ilias, Smoustopoulos Georgios, Evangelopoulos Maria-Eleptheria, Stefanis Leonidas, Kilidireas Costantinos
机构信息
2nd Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 1 Rimini Street, 12462 Athens, Greece.
Multiple Sclerosis & Demyelinating Diseases Unit, 1st Department of Neurology, Eginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Ther Adv Neurol Disord. 2022 Oct 8;15:17562864221127476. doi: 10.1177/17562864221127476. eCollection 2022.
Herein, we report a case of alopecia universalis and transient accommodation spasm presented after alemtuzumab administration in a patient previously treated with fingolimod. To the best of our knowledge, this is the first report of accommodation spasm as an acute adverse effect of alemtuzumab. Treatment with alemtuzumab in relapsing-remitting multiple sclerosis has been identified as a risk factor for developing secondary autoimmunity within the follow-up period (peak 18-36 months from the first infusion) such as thyroid disorders. This case highlights the need for postmarketing surveillance and the significance of reporting rare side effects related to alemtuzumab; its high efficacy should be weighted with potentially severe adverse events when making a therapeutic decision. Further studies in larger cohorts are needed to elucidate pathomechanisms of alemtuzumab.
在此，我们报告1例在先前接受芬戈莫德治疗的患者中，使用阿仑单抗后出现全秃和短暂性调节痉挛的病例。据我们所知，这是关于调节痉挛作为阿仑单抗急性不良反应的首例报告。复发缓解型多发性硬化症患者使用阿仑单抗治疗已被确定为在随访期（首次输注后18 - 36个月达到峰值）内发生继发性自身免疫的风险因素，如甲状腺疾病。该病例强调了上市后监测的必要性以及报告与阿仑单抗相关的罕见副作用的重要性；在做出治疗决策时，应权衡其高疗效与潜在的严重不良事件。需要在更大的队列中进行进一步研究以阐明阿仑单抗的发病机制。
Zotero 插件